Gossamer Bio Inc (GOSS)

Mar 13, 2025, 4:01 PM EDT - 22 days ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 7, 2025, 5:30 PM EST - 4 weeks ago

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 13, 2025, 7:42 PM EST - 7 weeks ago

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Feb 3, 2025, 7:01 AM EST - 2 months ago

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 28, 2025, 7:01 AM EST - 2 months ago

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Nov 7, 2024, 4:03 PM EST - 5 months ago

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Sep 10, 2024, 1:25 AM EDT - 7 months ago

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Aug 26, 2024, 4:01 PM EDT - 7 months ago

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Aug 20, 2024, 7:00 AM EDT - 8 months ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOVX IMRN

Aug 12, 2024, 4:01 PM EDT - 8 months ago

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Jun 25, 2024, 2:39 PM EDT - 10 months ago

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

May 14, 2024, 4:01 PM EDT - 11 months ago

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 7, 2024, 4:01 PM EDT - 11 months ago

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 7:46 AM EDT - 11 months ago

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

May 6, 2024, 7:30 AM EDT - 11 months ago

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 3, 2024, 8:02 AM EDT - 1 year ago

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Mar 12, 2024, 7:31 AM EDT - 1 year ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Mar 5, 2024, 7:31 AM EST - 1 year ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Dec 13, 2023, 4:01 PM EST - 1 year ago

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Dec 5, 2023, 7:01 AM EST - 1 year ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Nov 29, 2023, 7:01 AM EST - 1 year ago

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Nov 9, 2023, 7:31 AM EST - 1 year ago

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Oct 3, 2023, 4:08 PM EDT - 1 year ago

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Sep 7, 2023, 7:44 AM EDT - 1 year ago

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

Aug 8, 2023, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 4:16 PM EDT - 1 year ago

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

Jul 20, 2023, 7:56 AM EDT - 1 year ago

Gossamer Bio Announces $212 Million Private Placement Financing

May 18, 2023, 7:05 AM EDT - 2 years ago

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

May 9, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

Apr 2, 2023, 4:12 AM EDT - 2 years ago

Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib

Mar 17, 2023, 7:31 AM EDT - 2 years ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Jan 30, 2023, 4:48 AM EST - 2 years ago

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

Dec 8, 2022, 1:27 PM EST - 2 years ago

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Dec 6, 2022, 8:19 AM EST - 2 years ago

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

Dec 6, 2022, 7:15 AM EST - 2 years ago

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

Nov 3, 2022, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update

Oct 20, 2022, 3:35 PM EDT - 2 years ago

This little-known biopharma stock could rally 70%: Goldman Sachs

Aug 9, 2022, 8:01 AM EDT - 2 years ago

Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update

Jul 13, 2022, 7:15 AM EDT - 2 years ago

Gossamer Bio Announces $120 Million Private Placement Financing

Jun 9, 2022, 8:30 AM EDT - 3 years ago

Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib's Potential for the Treatment of PAH

May 10, 2022, 4:01 PM EDT - 3 years ago

Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update

Apr 25, 2022, 9:06 AM EDT - 3 years ago

Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program

Apr 25, 2022, 7:29 AM EDT - 3 years ago

Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update

Mar 3, 2022, 4:01 PM EST - 3 years ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update

Feb 28, 2022, 7:01 AM EST - 3 years ago

Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022

Nov 8, 2021, 8:39 PM EST - 3 years ago

Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 4:01 PM EST - 3 years ago

Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Nov 2, 2021, 4:01 PM EDT - 3 years ago

Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021